Foundayo vs Zepbound
Orforglipron (Foundayo) and tirzepatide (Mounjaro, Zepbound). What the research says about each, side by side. Every row comes from the studies and drug labels in the last row. More on each: Orforglipron and Tirzepatide.
| Orforglipron | Tirzepatide | |
|---|---|---|
| Category | GLP-1 and metabolic | GLP-1 and metabolic |
| Evidence | Extensive clinical research | Extensive clinical research |
| FDA status | FDA-approved as Foundayo on April 1, 2026 for chronic weight management in adults. Taken once a day, with or without food: the label sets no wait before eating. | FDA-approved as Mounjaro (2022, type 2 diabetes) and Zepbound (2023, weight management; 2024, sleep apnea with obesity). Compounded copies aren't FDA-approved. |
| How it works | It binds the GLP-1 receptor and triggers the same effects as GLP-1 shots: more insulin when sugar is high, slower stomach emptying and less appetite. | The GLP-1 part lowers appetite, slows the stomach and helps insulin release. GIP is a second gut hormone that also boosts insulin after meals and seems to add to the effect on appetite and fat tissue. Hitting both receptors with one molecule gives more weight loss than GLP-1 alone in head-to-head trials. |
| Half-life | About 29 to 49 hours, so it builds to a steady level after about a week of daily pills. Levels peak 4 to 8 hours after a dose. About 77% of a dose is absorbed, and food lowers that only a little. | About 5 days. Levels peak 8–72 hours after a shot and reach a steady level after about 4 weeks of weekly shots. |
| Studied for |
|
|
| Reported side effects |
|
|
| Sources |
|
|
